Amicus Therapeutics Inc (FOLD)

Currency in USD
14.270
0.000(0.00%)
Closed·
14.230-0.040(-0.28%)
·
FOLD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.27014.290
52 wk Range
5.51014.380
Key Statistics
Prev. Close
14.27
Open
14.27
Day's Range
14.27-14.29
52 wk Range
5.51-14.38
Volume
8.63M
Average Volume (3m)
10.5M
1-Year Change
48.4912%
Book Value / Share
0.75
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FOLD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.500
Upside
+1.61%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Amicus Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Amicus Therapeutics Inc Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics Inc Earnings Call Summary for Q3/2025

  • Amicus Therapeutics exceeded Q3 2025 expectations with EPS of $0.06 (100% above forecast) and revenue of $169.1 million (19% YoY growth), resulting in a 1.02% pre-market stock increase.
  • The company reported its first quarter of GAAP net income at $17.3 million and non-GAAP net income of $54.2 million, with cash reserves increasing by $32.8 million to $263.8 million.
  • Strong performance was driven by Galafold (12% growth, 69% market share) and Pombiliti/Opfolda (42% revenue surge) with successful international market expansion.
  • Management projects 15-22% total revenue growth for 2025, with Galafold growing 10-15% and Pombiliti/Opfolda increasing 50-65%, targeting combined sales of $1 billion by 2028.
  • The company is pursuing label expansions for its products while addressing challenges including market competition, regulatory hurdles, and potential supply chain disruptions.
Last Updated: 2025-11-04, 09:54 a/m
Read Full Transcript

Compare FOLD to Peers and Sector

Metrics to compare
FOLD
Peers
Sector
Relationship
P/E Ratio
−313.9x6.6x−0.6x
PEG Ratio
−3.620.000.00
Price/Book
19.2x2.7x2.6x
Price / LTM Sales
7.4x8.1x3.4x
Upside (Analyst Target)
1.6%175.2%42.0%
Fair Value Upside
Unlock9.4%5.0%Unlock

Analyst Ratings

0 Buy
7 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 14.500
(+1.61% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jefferies
Hold14.50+1.61%16.00DowngradeJan 22, 2026
Guggenheim
Hold---DowngradeJan 05, 2026
Leerink Partners
Hold14.50+1.61%17.00DowngradeDec 29, 2025
TD Cowen
Hold14.50+1.61%20.00DowngradeDec 22, 2025
Needham
Hold---DowngradeDec 19, 2025

Earnings

Latest Release
Nov 04, 2025
EPS / Forecast
0.06 / 0.03
Revenue / Forecast
169.06M / 165.44M
EPS Revisions
Last 90 days

FOLD Income Statement

People Also Watch

156.21
INSM
-2.61%
120.61
MHK
-3.70%
13.390
AMRX
-1.40%
63.41
CYTK
-2.34%

FAQ

What Is the Amicus (FOLD) Stock Price Today?

The Amicus stock price today is 14.270

What Stock Exchange Does Amicus Trade On?

Amicus is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Amicus?

The stock symbol for Amicus is "FOLD."

What Is the Amicus Market Cap?

As of today, Amicus market cap is 4.41B.

What Is Amicus's Earnings Per Share (TTM)?

The Amicus EPS (TTM) is -0.05.

When Is the Next Amicus Earnings Date?

Amicus will release its next earnings report on Feb 19, 2026.

From a Technical Analysis Perspective, Is FOLD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Amicus Stock Split?

Amicus has split 0 times.

How Many Employees Does Amicus Have?

Amicus has 499 employees.

What is the current trading status of Amicus (FOLD)?

As of Jan 25, 2026, Amicus (FOLD) is trading at a price of 14.270, with a previous close of 14.270. The stock has fluctuated within a day range of 14.270 to 14.290, while its 52-week range spans from 5.510 to 14.380.

What Is Amicus (FOLD) Price Target According to Analysts?

The average 12-month price target for Amicus is USD14.500, with a high estimate of USD14.5 and a low estimate of USD14.5. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +1.61% Upside potential.

What Is the FOLD Premarket Price?

FOLD's last pre-market stock price is 14.280. The pre-market share volume is 124,960.000, and the stock has decreased by 0.010, or 0.070%.

What Is the FOLD After Hours Price?

FOLD's last after hours stock price is 14.230, the stock has decreased by -0.040, or -0.280%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.